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ABSTRACT
Children with autism spectrum disorders (ASD) often suffer gastrointestinal problems consistent with imbalances in the
gut microbial population. Treatment with antibiotics or pro/prebiotics has been postulated to regulate microbiota and
improve gut symptoms, but there is a lack of evidence for such approaches, especially for prebiotics. This study assessed
the influence of a prebiotic galactooligosaccharide (B-GOS) on gut microbial ecology and metabolic function using faecal
samples from autistic and non-autistic children in an in vitro gut model system. Bacteriology was analysed using flow
cytometry combined with fluorescence in situ hybridization and metabolic activity by HPLC and 1H-NMR. Consistent with
previous studies, the microbiota of children with ASD contained a higher number of Clostridium spp. and a lower number of
bifidobacteria compared with non-autistic children. B-GOS administration significantly increased bifidobacterial
populations in each compartment of the models, both with autistic and non-autistic-derived samples, and lactobacilli in
the final vessel of non-autistic models. In addition, changes in other bacterial population have been seen in particular for
Clostridium, Rosburia, Bacteroides, Atopobium, Faecalibacterium prausnitzii, Sutterella spp. and Veillonellaceae. Furthermore, the
addition of B-GOS to the models significantly altered short-chain fatty acid production in both groups, and increased
ethanol and lactate in autistic children.
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INTRODUCTION
Autism typically develops in childhood, and it is considered as
‘a systemic spectrum disorder with multiple development tra-
jectories with an incidence four times higher in males than in
females’ (Grossi and Terruzzi 2014). In addition to behavioural
traits, GI abnormalities such as diarrhoea, constipation, bloat-
ing and abdominal pain are common in autism and they seem to
contribute to, and exacerbate, overall behaviour of children (ir-
ritability, sleeplessness, posturing) (Van De Sande, Van Buul and
Brouns 2014). A crosstalk exists between the gut microbiota and
central nervous system (CNS) mediated via a range of different
chemical, immunological and signalling interactions that form
part of the gut–brain axis. Several studies have demonstrated
the role of the gut microbiota in neurodevelopment and mental
health (Foster and McVey Neufeld 2013), and there is increasing
evidence associating gut microbial dysbiosis with GI problems
that might affect autistic children.
Bacteria such as Clostridium spp., Desulfovibrio spp. and Strep-
tococcus spp. are dominant in the guts of children with ASD.
Finegold et al. (2002) found nine unique species of clostridia in
autistic children comparedwith controls. Song, Liu and Finegold
(2004), using qPCR analysis, found higher levels of Clostridium
bolteae and Clostridium clusters I and XI. Furthermore, Parracho
et al. (2005), using FISH analysis, found greater number of species
derived from the C. histolyticum group (Clostridium clusters I and
II). Desulfovibrio group was found to be 10 times higher in the gut
microbiota of autistic children comparedwith controls (Finegold
et al. 2010; Finegold 2011).
High-throughput sequencing has been used in more recent
studies to determine bacterial composition of faecal samples
from autistic children. The genera Prevotella, Coprococcus and un-
classified Veillonellaceae have been found in lower abundance
in autistic individuals (Kang et al. 2013) with high genus Sut-
terella spp. (Williams et al. 2012; Wang et al. 2013). In addition, Bi-
fidobacterium species decreased in ASD, comparingwith the non-
autistic control (De Angelis et al. 2013).
Metabolic associations have also been identified with ASD
and may be attributed to gut dysbiosis in autistic individuals.
Abnormalities have been reported in tryptophan metabolism
where higher amount of indole derivatives in the blood and
higher levels of IAG (indolyl-acryloyl-glycine) in the urine of
autistic children have been identified. Increased abundance of
Clostridium spp. in the ASD-associated microbiota may con-
tribute to these metabolic alterations as these organisms can
metabolise tryptophan (Bingham 2003). Metabolomic studies
also identified alterations in nicotinic acidmetabolism (Yap et al.
2010) and amino acid deficiencies in autism with restricted di-
ets, modified gut microbial population and GI symptoms being
suggested as potential contributors (Ming et al. 2012).
Modulation of gutmicrobiota is an interesting potential strat-
egy to reduce presence of harmful microorganisms and their
metabolites that might be involved in negative stimulation of
CNS and affect behaviour (Shaw, Kassen and Chaves 1995; San-
dler et al. 2000). Treating GI disorders in ASD with antibiotics or
pro/prebiotics has been postulated to regulate microbiota and
improve gut symptoms, but the evidence is scarce, especially for
prebiotics.
The bifidogenic properties of B-GOS (Bimuno R©, Clasado Bio-
sciences Ltd, Buckinghamshire, UK) have been investigated in
vitro and in human intervention studies involving healthy volun-
teers, and conditions that have a purportedmicrobial input such
as IBS, travellers’ diarrhoea and obesity (Tzortzis et al. 2005; De-
peint et al. 2008; Vulevic et al. 2008; Drakoularakou et al. 2009; Silk
et al. 2009; Vulevic et al. 2013). Recently, B-GOS was also shown
to reduce cortisol secretion and anxiety in healthy volunteers
(Schmidt et al. 2015). Cortisol is a reliablemarker of stress andhy-
pothalamic pituitary adrenal axis activity. B-GOS supplementa-
tion lowered cortisol reactivity andmodulated attention to emo-
tional stimuli compared with a placebo group, supporting the
hypothesis that gut microbiota might have a role in behavioural
traits (Schmidt et al. 2015).
Our study aimed to assess the effects of B-GOS (65%GOS con-
tent) on gutmicrobial ecology andmetabolic end products ofmi-
crobial fermentation. We used in vitro, three-stage, continuous
gut model systems, inoculated with faecal samples of autistic
and non-autistic children, which simulated different physico-
chemical characteristics of the proximal, transverse and distal
colons.
MATERIALS AND METHODS
Substrate
TheB-GOSproductwas supplied byClasado Biosciences Ltd. The
mixture was in syrup format consisting of 65% (w/v) GOS, 10.1%
(w/v) lactose, 22% (w/v) glucose and 1.8% (w/v) galactose.
Faecal inoculation
Faecal samples were obtained from three non-autistic children
and three autistic child donors (male, aged 5–10 years old) who
were free of any metabolic and gastrointestinal diseases, were
not taking probiotic or prebiotic supplements and had not taken
antibiotics 6 months before faecal sample donation. Autistic
children had formal diagnosis of mild autism. None of the chil-
dren followed any specific or restricted diet.
All parents were then provided written informed consent for
use of their children’s faeces in the study. This study was ap-
proved by The University of Reading research Ethics Commit-
tee (UREC 15/20). Faecal samples were placed in an anaerobic
jar (AnaeroJarTM 2.5 L, Oxoid Ltd) including a gas-generating kit
(AnaeroGenTM, Oxoid). An aliquot of 20 g of sampleswas diluted
in 100mLanaerobic PBS (0.1mol/L phosphate buffer solution, pH
7.4, w/w) and homogenised (Stomacher 400, Seward, West Sus-
sex, UK) for 2 min at 240 paddle beats per minute. Samples were
added to anaerobic fermenters within 15 minutes of voiding.
Three-stage continuous culture gut model system
Physicochemical conditions in the colon were replicated in a
continuous culture system, comprised of a cascade of three glass
fermenters of increasing working volume connected in series. A
small-scale version of the validated system described by Mac-
farlane, Macfarlane and Gibson (1998) was used in this study,
with vessels (V) representing the proximal (V1, 80 mL, pH = 5.5),
transverse (V2, 100 mL, pH = 6.2) and distal colon (V3, 120 mL,
pH = 6.8). The systems were inoculated with 20% (wt:v) faecal
homogenate from either non-autistic and autistic children vol-
unteers in a growth medium (Macfarlane, Macfarlane and Gib-
son 1998). Following inoculation, the colonic model was run as
a batch culture for 24 h in order to stabilise bacterial popula-
tions prior to the initiation of medium flow. After 24 h (T0), the
medium flow was initiated and the system ran for at least 8
full volume turnovers to allow for steady state to be achieved
(SS1). Short-chain fatty acid (SCFA) profiles (±5%) were assessed
before starting B-GOS administration. Taking into account the
operating volume (300 mL) and the retention time (48 h, flow
rate 6.25 mL/h) of the colonic model system, a syrup containing
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GOS (2 g/daily, equivalent to 1 g of GOS) was added daily into
V1. The syrup was added to the system for at least a further 8
volume turnovers upon which steady state 2 (SS2) was achieved.
Aliquots of 4.5 mL were removed at SS1 and SS2.
SCFAs analysis by HPLC
The production of SCFAs in the fermentations was determined
by HPLC (Merck, NJ) as previously described by Rodriguez-
Colinas et al. (2013). Twenty microlitres of each sample was in-
jected with a run time of 45 min. Peaks were integrated using
Atlas Lab managing software (Thermo Lab Systems, Mainz, Ger-
many). Quantification of the samples was obtained through cal-
ibration curves of lactic, acetic, propionic, butyric and formic
acids in concentrations 12.5, 25, 50, 75 and 100mM, respectively.
In vitro enumeration of bacterial population by
FISH-FCM
Bacterial composition in the gut models was analysed for us-
ing fluorescence in situ hybridization combined with flow cy-
tometry (FISH-FCM). Seven hundred and fiftymicrolitres of sam-
ples were centrifuged at 1136 × g for 5 min. Pellets were resus-
pended in 375 μL of filtered PBS (using a 0.22-μm PVDF mem-
brane) and fixed in 1125 μL of 4% (v/v) paraformaldehyde. Af-
ter 4 h of incubation at 4◦C, samples were washed twice using
1 mL of PBS, resuspended in 600 μL PBS-ethanol (1:1, v/v) and
stored at –20◦C. Permeabilisation steps were performed using 30
μL of the fixed samples added to 500 μL PBS and centrifuged at
1136 × g for 3 min. Pellets were resuspended using 100 μL of
filtered TE-FISH (Tris/HCl 1 M pH 8, EDTA 0.5 M pH 8, distilled
H2O, 0.22 μm PVDF membrane) containing lysozyme (1 mg/mL
of 50 000 U/mg protein) and incubated for 10 min at room tem-
perature. Solutions containing the samples were then vortexed
and centrifuged at 1136 × g for 3 min. Pellets were washed
with 500 μL PBS and centrifuged (1136 × g, 3 min). Hybridis-
ations were performed by resuspending the pellets in 150 μL
of hybridisation buffer (5 M NaCl, 1 M Tris/HCl pH 8, 30% for-
mamide, ddH2O, 10% SDS), vortexed and centrifuged (1136 × g,
3 min). Pellets were then resuspended in 1 mL of hybridisation
buffer and 50 μL aliquoted into Eppendorf tubes. The probes
used (Sigma Aldrich Ltd, Poole, Dorset, UK) are reported in Ta-
ble 1 (Devereux et al. 1992; Wallner, Amann and Beisker 1993;
Langendijk et al. 1995; Poulsen et al. 1995; Manz et al. 1996; Franks
et al. 1998; Stoffel et al. 1998; Daims et al. 1999; Harmsen et al.
1999, 2000, 2002; Hold et al. 2003; Lay et al. 2005; Walker et al.
2005; Kong et al. 2012). NON EUB338 and EUB338 I-II-III linked
at their 5′ end either to Alexa488 or Alexa647. Group-specific
probeswere linkedwithAlexa647 at their 5′ end. Fourmicrolitres
of each probe and 4 μL of Eub338 I-II-III (linked to Alexa488)
Table 1.Oligonucleotide probes used in this study for FISH-FCM analysis of bacterial populations. +: These probes are used together in equimo-
lar concentration of 50 ng/μL.
Probe name Sequence (5′ TO 3′) Target group Reference
Non Eub ACTCCTACGGGAGGCAGC Wallner, Amann and
Beisker (1993)
Eub338 I + GCT GCC TCC CGT AGG AGT Most bacteria Daims et al. (1999)
Eub338 II + GCA GCC ACC CGT AGG TGT Planctomycetales Daims et al. (1999)
Eub338 III + GCT GCC ACC CGT AGG TGT Verrucomicrobiales Daims et al. (1999)
Bif164 CAT CCG GCA TTA CCA CCC Most Bifidobacterium spp. and Parascardovia
denticolens
Langendijk et al. (1995)
Lab158 GGTATTAGCAYCTGTTTCCA Most Lactobacillus, Leuconostoc and Weissella spp.;
Lactococcus lactis; all Vagococcus, Enterococcus,
Melisococcus, Tetragenococcus, Catellicoccus,
Pediococcus and Paralactobacillus spp,
Harmsen et al. (1999)
Bac303 CCA ATG TGG GGG ACC TT Most Bacteroidaceae and Prevotellaceae, some
Porphyromonadaceae
Manz et al. (1996)
Clit135 GTTATCCGTGTGTACAGGG Some of the Clostridium lituseburense group
(Clostridium cluster XI)
Manz et al. (1996)
Erec482 GCT TCT TAG TCA RGT ACCG Most of the Clostridium coccoides-Eubacterium
rectale group(Clostridium clusters XIVa and XIVb)
Manz et al. (1996)
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium histolyticum group
(Clostridium clusters I and II)
Franks et al. (1998)
Rrec584 TCA GAC TTG CCG YAC CGC Roseburia subcluster Franks et al. (1998)
Prop853 ATT GCG TTA ACT CCG GCAC Clostridial cluster IX Walker et al. (2005)
Ato291 GGT CGG TCT CTC AAC CC Atopobium, Colinsella, Olsenella and Eggerthella
spp.; Cryptobacterium curtum; Mycoplasma
equigenitalium and Mycoplasma elephantis
Harmsen et al. (2000)
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii and related sequences Hold et al. (2003)
DSV687 TAC GGA TTT CAC TCC T Most Desulfovibrionales (excluding Lawsonia) and
many Desulfuromonales
Devereux et al. (1992)
EC1531 CACCGTAGTGCCTCGTCATCA Escherichia coli BJ4 Poulsen et al. (1995)
Rbro730 + TAAAGCCCAGYAGGCCGC Clostridium sporosphaeroides, Ruminococcus bromii,
Clostridium leptum
Harmsen et al. (2002); Lay
et al. (2005)
Rfla729 + AAA GCC CAG TAA GCC GCC Ruminococcus albus, R. flavefaciens Harmsen et al. (2002); Lay
et al. (2005)
SUBU1237 CCC TCT GTT CCG ACC ATT Burkholderia spp., Sutterella spp. Stoffels et al. (1998)
Vei723 ACA CAG TCC AGA AAG GCG Veillonellaceae Kong et al. (2012)
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were added to the working solution and incubated overnight at
35◦C in a heating block. After 12 h of incubation, an aliquot of
150 μL hybridisation buffer was added to the working solution,
vortexed and centrifuged (1136 × g, 3 min). One hundred and
fifty microlitres of supernatant were removed from each sample
and the remaining volume was centrifuged (1136 × g, 3 min).
The pellets were washed with 200 μL of washing buffer (5 M
NaCl, 1 M Tris/HCl pH 8, 0.5 M EDTA pH 8, ddH2O, 10% SDS),
homogenised by vortexing and incubated for 20 min at 37◦C
in a heating block. Afterwards the samples were centrifuged
(1136 × g, 3 min) and supernatants were removed. Negative con-
trol samples (no probes added) were screened by FCM to detect
background before the probe samples were resuspended in an
appropriate amount of PBS. Samples were stored at 4◦C until
determinations. Numbers of specific and total bacteria were de-
termined taking into account dilution factor, calculated from
different volumes used in samples preparation steps, and
events/μL obtained from NON EUB338 and EUB338 I-II-III probes
analysed by FCM.
Metabolic analysis by 1H-NMR
Three consecutive days of the three biological replicates for each
group (autistic and non-autistic) of all time points (before and
after treatment) were analysed by 1H-NMR (n = 27, each group).
Fermentation supernatants were defrosted, vortexed and cen-
trifuged at 599 × g for 5 min. The supernatants were filtered us-
ing 0.22 μm low protein binding Durapore polyvianylidene flu-
oride (PVDF) membranes (Millex; EMD Millipore, Billerica, MA,
USA) and 400 μL transferred into fresh Eppendorf tubes. Filtered
samples were combined with 200 μL of phosphate buffer (0.2 M
(pH 7.4) in D2Oplus 0.001%TSP),mixed by vortexing, centrifuged
at 1136 × g for 10 min and then 550 μL was transferred into 5
mmNMR tubes for analysis. All NMR spectra were acquired on a
Bruker Avance DRX 500 MHz NMR spectrometer (Bruker Biopsin,
Rheinstetten, Germany) operating at 500 MHz. They were ac-
quired using a standard 1D pulse sequence [recycle delay (RD)-
90◦-t1-90◦-tm-90◦-acquire free induction decay (FID)] with water
suppression applied during RD of 2 s, a mixing time Tm of 100
ms and a 90 pulse set at 7.70 μs. For each spectrum, a total of
128 scanswere accumulated into 64 k data points with a spectral
width of 12 001 ppm. The FIDsweremultiplied by an exponential
function corresponding to 0.3 Hz line broadening.
Data preprocessing and analysis
All spectra were manually phased, baseline corrected and
calibrated to the chemical shift of TSP (3-(trimethylsilyl)-
[2,2,3,3,−2H4]-propionic acid, δ 0.00). Spectra were digitised us-
ing an in-house MATLAB (version R2014a, The Mathworks, Inc.;
Natwick, MA) script. The spectral region containing the water
resonance was removed to minimise distortions in the baseline
arising from imperfect water saturation. Median fold normal-
ization was performed for both groups: non-autistic and autis-
tic children. Before and after administration of B-GOS, princi-
pal components analysis (PCA) using mean-centred data was
applied. Orthogonal projection to latent structure discriminant
analysis (OPLS-DA) models was constructed using unit variance
scaling for pairwise comparisons of the different experimental
groups and time points. Correlation coefficients plots were gen-
erated from the model outputs by back scaling transformation
to display the contribution of each variable (metabolites) to sam-
ple classification (e.g. before and after treatment). Colour repre-
sents the significance of correlation (R2) for each metabolite to
class membership. Predictive strength (Q2Y) of the models was
obtained using a 7-fold cross-validation method and these were
validated using permutation testing (number of permutations =
10 000).
Statistical analysis
Data from HPLC and FMC-FISH analyses were analysed using
paired t-test in order to assess significance of results, comparing
the two time points SS1 and SS2, before and after treatment, re-
spectively. Statistical significancewas at P< 0.05 for all analyses.
Analyses were performed using GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA, USA).
RESULTS
Bacterial enumeration
Changes in bacterial compositions in gut model systems are re-
ported in Fig. 1. The data showed lower numbers of bifidobacte-
ria in ASD models compared with non-autistic ones. Significant
increases in the Bifidobacterium spp., following the addition of
B-GOS to models containing both autistic and non-autistic sam-
ples, were seen. In autistic models, a significant increase of bifi-
dobacteria occurred from 5.32 to 7.27 log10 cells/mL (P < 0.01),
from 4.81 to 6.79 log10 CFU/mL (P < 0.001) and from 5.57 to
6.83 log log10 cells/mL (P < 0.05), in V1, V2 and V3, respectively.
A slight but significant increase in Clostridium cluster XI in V2
for autistic children was also found, as well as significant de-
crease in V2 in Veillonellaceae group from 6.06 to 5 log10 CFU/mL
(P < 0.05). In non-autistic models, there was a significant in-
crease in numbers of bifidobacteria in V1, from 5.83 to 7.16
log log10 cells/mL (P < 0.01), and in V3, from 4.97 to 6.73 log10
cells/mL (P < 0.001) and in lactic acid bacteria (Lab158) in V3
from 5.13 to 6.01 log10 cells/mL (P < 0.05). Additionally, B-GOS
slightly increased Roseburia spp. in V1 and V3 (P < 0.05) and re-
duced Atopobium spp. from 6.06 to 5.28 log10 cells/mL and Fae-
calibacterium prausnitzii from 6.78 to 5.27 log10 cells/mL (P < 0.05
for both) in the second vessel, while increasing Atopobium spp.
from 5 to 5.92 log10 cells/mL (P < 0.05) in the third vessel of
non-autistic models. In these models, numbers of Clostridium
coccoides–Eubacterium rectalewere also increased from 6.76 to 7.08
log10 cells/mL (P < 0.01) in V1 and Sutterella spp. significantly de-
creased in V1 from 7.05 to 6.49 (P < 0.01) and V2 from 7.02 to 6.37
log10 CFU/mL (P < 0.05) after B-GOS administration. There was
a general trend to increase all other bacterial groups analysed
in all vessels but this was not significant. Exceptions were seen
for Bacteroides (V1), Clostridial cluster IX (V1), F. prausnitzii (V1),
Escherichia coli (V3), Ruminococcus spp., Clostridium leptum (V2),
Sutterella spp. and Veillonellaceae (all vessels) in autistic mod-
els, and for Clostridium coccoides–Eubacterium rectale (V2), Atopo-
bium spp. (V1), Clostridial cluster IX (V2), Clostridium cluster XI
(V1, V2), E. coli (V2), Sutterella spp. and Veillonellaceae (all ves-
sels) in non-autistic models that slightly decreased.
SCFAs production
SCFA concentrations are shown in Fig. 2. Our data show a lower
concentration of butyrate and propionate in autistic models,
compared with non-autistic models, but no differences in ac-
etate before adding B-GOS into the system. After the adminis-
tration of B-GOS, acetate and butyrate were the main end prod-
ucts of microbial fermentation. Supplementation of B-GOS to
gut models inoculated with faecal samples from autistic chil-
dren led to a significant increase of acetate and butyrate in V1
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Figure 1. Bacterial groups detected by FISH-FCM (Log10 CFU/mL) in culture broth recovered from each vessel (V1, V2 and V3) of a colonic model before (SS1) and after
(SS2) the daily administration of B-GOS (2 g/d, equivalent to 1 g GOS). Significant difference after the treatment: ∗ P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001. Probes: total bacteria
(Eub338I-II-III), Bifidobacterium spp. (Bif164), Lactobacillus spp. (Lab158), most Bacteroidaceae and Prevotellaceae (Bac303), Clostridium coccoides–Eubacterium rectale group
(Erec482), Roseburia subcluster (Rrec584), F. prausnitzii (Fprau655), Clostridium cluster XI (Clit135), Sutterella spp. (SUBU1237), Veillonellaceae (VEI732), Atopobium spp.
(Ato291). (A) Autistic children; (B) non-autistic children.
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Figure 2. HPLC analysis. Acetate, propionate and butyrate concentrations in culture broths recovered from vessels (V1, V2 and V3) of in vitro gut model systems before
(SS1) and after (SS2) administration of B-GOS (1 g/daily GOS). Results are reported as means (mM) of the data (n = 3): (A) autistic children and (B) non-autistic children.
Significant difference after the treatment: ∗ P < 0.05; ∗∗∗P < 0.001.
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Figure 3. 1H-NMRdata analysis. (A) PCA score plot shows a separation betweenmodels inoculatedwith stool samples of non-ASD andASD children after administration
of B-GOS. Dark and light blue dots represent replicates of samples from gut models inoculated with faecal samples of autistic children, before (SS1) and after (SS2)
treatment, respectively. Yellow and red dots represent replicates of samples from gut models inoculated with faecal samples of non-autistic children, before (SS1)
and after (SS2) treatment, respectively. (B) Correlation coefficients indicating the associations of identified metabolites with autism and their alteration upon B-GOS
administration. SS1: before treatment; SS2: after treatment. White cells represent no significant correlations.
andV2, simulating the proximal and transverse colons (P< 0.05),
respectively, while concentration of propionate was decreased
(P < 0.05) in V3mimicking distal colon. Inmodels simulating the
colon of non-autistic children, the fermentation of B-GOS me-
diated significant production of acetate (P < 0.05) and butyrate
(P < 0.001) in V2 and V3, simulating the transverse and distal
colon, respectively. There was no effect on propionate.
1H-NMR spectroscopic profiles
PCA was performed on mean-centred data to summarise vari-
ance with the dataset. The scores plot (PC1 versus PC2) shown
in Fig. 3A showed separation between autistic and non-autistic
models after treatment, indicating that B-GOS supplementation
contributed to the largest source of variance in the metabolic
data. Comparison of the spectra profiles from gut models be-
fore and after treatment identified that a number of metabolites
changed following B-GOS supplementation to characterise the
metabolic variation associated with ASD, B-GOS supplementa-
tion and differences in microbial response to B-GOS between
the ASD and non-ASD microbiota. The results of these anal-
yses are summarised in Fig. 3B. A significant OPLS-DA model
was obtained comparing the metabolic profiles of the autis-
tic and non-autistic models at baseline (Q2Y = 0.07; P < 0.05;
Fig. SC-I, Supporting Information). Supernatants from the autis-
tic models contained greater amounts of ethanol, glycine, ty-
rosine, tyramine, 5-aminopentoanate, acetate, 4-aminobutyrate
and betaine, and lower amounts of butyrate compared with
the non-autistic models. B-GOS supplementation was found
to modulate the metabolic profile of the autistic models (Q2Y
= 0.08; P < 0.05) increasing ethanol, lactate, acetate and bu-
tyrate and decreasing propionate and trimethylamine (Fig. SB-
I, Supporting Information). Increased butyrate and acetate pro-
duction was also observed in the non-autistic models follow-
ing the addition of BGOS (Q2Y = 0.12; P < 0.01; Fig. SB-II, Sup-
porting Information). Comparing the metabolic profiles of the
autistic and non-autistic models after B-GOS feeding (Q2Y =
0.17; P < 0.01) revealed that some of the metabolic variation
was reduced (Fig. SC-II, Supporting Information). There was no
longer variation in 4-aminobutyrate between the models; how-
ever, the difference in ethanol and acetate between autistic and
non-autistic models was increased being higher in the autistic
models.
DISCUSSION
Recent studies have focused on the effect of pre/probiotics on
the gut–brain axis (Liu, Cao and Zhang 2015). This study investi-
gated the influence of B-GOS on a small scale, in vitro, gut model
system inoculated with faeces from autistic and non-autistic
children. The results showed a positive modulation of bacterial
populations, using an automated FISH method combined with
FCM. We also assessed metabolic profiles and key metabolites
in both test groups.
Lower concentrations of SCFAs have previously been found
in children with ASD by Adams et al. suggesting a reduced fer-
mentation capacity by the ASD microbiota. It was hypothesised
that this was due to a compromised microbiota characterised
by a lower number of bifidobacteria, consistent with microbial
signatures observed here (Adams et al. 2011). Concomitant with
these population changes, functional alterations were also ob-
served in both autistic and non-autisticmodels with acetate and
butyrate, the main end products of microbial fermentation, be-
ing increased.
Recent studies have focussed on SCFAs and their effect on
the CNS. These fermentation products can cross the blood–brain
barrier and might influence early brain development. The syn-
thesis of neuroactive compounds such as dopamine and sero-
tonin can be modulated by SCFA and they are able to produce
reversible psychological and physiological changes in rats sim-
ilar to those found in ASDs (Wang et al. 2011). Experimental
evidence using intraventricular infusion in rats indicates that
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propionic acid can produce brain and behavioural changes sim-
ilar to ASD (MacFabe et al. 2008).
Recent ASD studies have shown increase in numbers of Sut-
terella spp. and decrease in Veillonellaceae group. In this study,
the results did not showany significant differences betweenASD
and non-ASD group. However, a general decrease in those bac-
terial groups after treatment was highlighted, suggesting that
B-GOS administration might have an impact on the growth of
these ASD-associated bacteria.
Following B-GOS feeding, the microbiota of autistic chil-
dren produced greater amount of ethanol and lactate while the
amount of amino acids and the SCFA propionate, present in the
model, was reduced. These metabolic alterations were not ob-
served when the faecal microbiota of non-autistic individuals
were fed B-GOS. In a healthy colon, lactate production is gen-
erally low due to its conversion to other organic acids by many
bacteria and because lactate can be used as a substrate for dis-
similation of sulphate by some bacteria (e.g. Desulfovibrio spp.)
(Fite et al. 2004; Marquet et al. 2009; Flint et al. 2014). In children
with ASD, the presence of lactate is interesting because its ac-
cumulation has been associated with neurological problems, in
particular studies show the effect of lactate infusions on anxiety
and panic disorders (Cowley et al. 1987; Dillon et al. 1987). Cow-
ley and colleagues in their findings showed that lactate infusion
in patients suffering from panic disorder provokes higher panic
symptoms reaction compared with controls (Dillon et al. 1987).
Dillon et al. have showed similar results in in vivo, where panic
and anxiety reaction has been measured using Acute Panic In-
ventory scores. After lactate infusions, the scores were much
higher in patients with panic and anxiety disorders compared
with normal controls (Cowley et al. 1987).
The lysine degradation product, 5-aminopentanoic acid, was
also higher in the autistic compared with the non-autistic mod-
els. This metabolite can be produced both endogenously and
through the bacterial catabolism of lysine. It is believed to
act as a methylene homologue of γ -aminobutyric acid (GABA)
and functions as a weak GABA agonist (Callery and Geelhaar
1985). Interestingly, GABA was also higher in the autistic models
comparedwith the non-autisticmodels pre-treatment but these
differenceswere not present following B-GOS treatment. Certain
bacteria, such as lactobacilli, are able to produce molecules that
act as neurotransmitters and directly affect the brain (Wall et al.
2014). In our results, its reductionmight be due to changes in gut
microbiota composition.
Ethanol was found in higher amount in ASD children com-
paring with non-ASD children. The vast majority of bacteria
form ethanol from acetyl-CoA and the glycolytic pathway (Mac-
farlane and Macfarlane 2003). Microorganisms are able to oxi-
dase ethanol and the impact of bacterial overgrowth on ethanol
production has previously been studied (Baraona et al. 1986).
Metabolism of ethanol can lead to the production of toxic end
products such as acetaldehyde, which may affect the gastroin-
testinal mucosa. The role of acetaldehyde in ASD has been re-
cently evaluated in particular for its role in oxidative stress and
DNA damage. Under healthy conditions, ethanol is converted
into acetic acid in the liver by a two-step process involving al-
cohol dehydrogenase and aldehyde dehydrogenase (ALDH). Mu-
tation of the ALDH gene has been shown to increase the ac-
cumulation of acetaldehyde and result in cancers within dif-
ferent regions of the gastrointestinal tract and Alzheimer’s dis-
ease (Jurnak 2015). The potential role of this toxic compound
in neurological disorders, including autism, warrants further
exploration.
CONCLUSIONS
This in vitro study showed promising and positive results in
that supplementing the microbiota of children with ASD with
65%B-GOS may manipulate the gut bacterial population and al-
ter metabolic activity towards a configuration that might repre-
sent a health benefit to the host. However, further work will be
required to assess such changes in an in vivo human interven-
tion study.
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